Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Post-translational modifications of Runx1 regulate its activity in the cell.

Wang L, Huang G, Zhao X, Hatlen MA, Vu L, Liu F, Nimer SD.

Blood Cells Mol Dis. 2009 Jul-Aug;43(1):30-4. doi: 10.1016/j.bcmd.2009.03.005. Epub 2009 Apr 21. Review.

2.

Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity.

Zhao X, Jankovic V, Gural A, Huang G, Pardanani A, Menendez S, Zhang J, Dunne R, Xiao A, Erdjument-Bromage H, Allis CD, Tempst P, Nimer SD.

Genes Dev. 2008 Mar 1;22(5):640-53. doi: 10.1101/gad.1632608.

3.

[Epigenetic mechanism of RUNX1 in pathogenesis of leukemia].

Zhang H, Zheng HY.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Apr;18(2):525-30. Review. Chinese.

PMID:
20416203
4.

RUNX1 associates with histone deacetylases and SUV39H1 to repress transcription.

Reed-Inderbitzin E, Moreno-Miralles I, Vanden-Eynden SK, Xie J, Lutterbach B, Durst-Goodwin KL, Luce KS, Irvin BJ, Cleary ML, Brandt SJ, Hiebert SW.

Oncogene. 2006 Sep 21;25(42):5777-86. Epub 2006 May 1.

PMID:
16652147
5.

Posttranslational modifications of RUNX1 as potential anticancer targets.

Goyama S, Huang G, Kurokawa M, Mulloy JC.

Oncogene. 2015 Jul;34(27):3483-92. doi: 10.1038/onc.2014.305. Epub 2014 Sep 29. Review.

PMID:
25263451
6.

Loss of RUNX1/AML1 arginine-methylation impairs peripheral T cell homeostasis.

Mizutani S, Yoshida T, Zhao X, Nimer SD, Taniwaki M, Okuda T.

Br J Haematol. 2015 Sep;170(6):859-73. doi: 10.1111/bjh.13499. Epub 2015 May 26.

7.

Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediated lysozyme repression.

Claus R, Fliegauf M, Stock M, Duque JA, Kolanczyk M, Lübbert M.

J Leukoc Biol. 2006 Dec;80(6):1462-72. Epub 2006 Sep 25.

PMID:
17000900
8.

Histone arginine methylation keeps RUNX1 target genes in an intermediate state.

Herglotz J, Kuvardina ON, Kolodziej S, Kumar A, Hussong H, Grez M, Lausen J.

Oncogene. 2013 May 16;32(20):2565-75. doi: 10.1038/onc.2012.274. Epub 2012 Jul 9.

PMID:
22777353
9.

The hematopoietic transcription factor AML1 (RUNX1) is negatively regulated by the cell cycle protein cyclin D3.

Peterson LF, Boyapati A, Ranganathan V, Iwama A, Tenen DG, Tsai S, Zhang DE.

Mol Cell Biol. 2005 Dec;25(23):10205-19.

10.

Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs.

Maiques-Diaz A, Chou FS, Wunderlich M, Gómez-López G, Jacinto FV, Rodriguez-Perales S, Larrayoz MJ, Calasanz MJ, Mulloy JC, Cigudosa JC, Alvarez S.

Leukemia. 2012 Jun;26(6):1329-37. doi: 10.1038/leu.2011.376. Epub 2012 Jan 13.

PMID:
22289984
11.

The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes.

Bakshi R, Zaidi SK, Pande S, Hassan MQ, Young DW, Montecino M, Lian JB, van Wijnen AJ, Stein JL, Stein GS.

J Cell Sci. 2008 Dec 1;121(Pt 23):3981-90. doi: 10.1242/jcs.033431. Epub 2008 Nov 11.

12.

Runx1 Phosphorylation by Src Increases Trans-activation via Augmented Stability, Reduced Histone Deacetylase (HDAC) Binding, and Increased DNA Affinity, and Activated Runx1 Favors Granulopoiesis.

Leong WY, Guo H, Ma O, Huang H, Cantor AB, Friedman AD.

J Biol Chem. 2016 Jan 8;291(2):826-36. doi: 10.1074/jbc.M115.674234. Epub 2015 Nov 23.

13.

AML-1-ETO-Mediated erythroid inhibition: new paradigms for differentiation blockade by a leukemic fusion protein.

Choi Y, Elagib KE, Goldfarb AN.

Crit Rev Eukaryot Gene Expr. 2005;15(3):207-16. Review.

PMID:
16390317
14.

Histone deacetylase inhibitors trichostatin A and valproic acid circumvent apoptosis in human leukemic cells expressing the RUNX1 chimera.

Sasaki K, Yamagata T, Mitani K.

Cancer Sci. 2008 Feb;99(2):414-22. doi: 10.1111/j.1349-7006.2007.00699.x.

15.

AML1-ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia.

Fu L, Huang W, Jing Y, Jiang M, Zhao Y, Shi J, Huang S, Xue X, Zhang Q, Tang J, Dou L, Wang L, Nervi C, Li Y, Yu L.

FEBS J. 2014 Feb;281(4):1123-31. doi: 10.1111/febs.12673. Epub 2014 Jan 10.

16.

The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations.

Huang G, Zhao X, Wang L, Elf S, Xu H, Zhao X, Sashida G, Zhang Y, Liu Y, Lee J, Menendez S, Yang Y, Yan X, Zhang P, Tenen DG, Osato M, Hsieh JJ, Nimer SD.

Blood. 2011 Dec 15;118(25):6544-52. doi: 10.1182/blood-2010-11-317909. Epub 2011 Oct 19.

17.

A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.

Yan M, Kanbe E, Peterson LF, Boyapati A, Miao Y, Wang Y, Chen IM, Chen Z, Rowley JD, Willman CL, Zhang DE.

Nat Med. 2006 Aug;12(8):945-9. Epub 2006 Jul 30.

PMID:
16892037
18.

Contributions of the histone arginine methyltransferase PRMT6 to the epigenetic function of RUNX1.

Lausen J.

Crit Rev Eukaryot Gene Expr. 2013;23(3):265-74. Review.

PMID:
23879542
19.

RUNX1-RUNX1 homodimerization modulates RUNX1 activity and function.

Li D, Sinha KK, Hay MA, Rinaldi CR, Saunthararajah Y, Nucifora G.

J Biol Chem. 2007 May 4;282(18):13542-51. Epub 2007 Mar 13.

20.

Identification of AML1-ETO modulators by chemical genomics.

Corsello SM, Roti G, Ross KN, Chow KT, Galinsky I, DeAngelo DJ, Stone RM, Kung AL, Golub TR, Stegmaier K.

Blood. 2009 Jun 11;113(24):6193-205. doi: 10.1182/blood-2008-07-166090. Epub 2009 Apr 17.

Supplemental Content

Support Center